Imaging Diagnostic Systems could soon make the jump from a development-stage company to a full-fledged vendor of medical systems. The company has received regulatory approval to apply the CE Mark to its computed tomography laser mammography (CTLM) system
Imaging Diagnostic Systems could soon make the jump from a development-stage company to a full-fledged vendor of medical systems. The company has received regulatory approval to apply the CE Mark to its computed tomography laser mammography (CTLM) system and is now clear to begin marketing the product in countries in the European Union.
The CE mark is accepted in other parts of the world, the company noted, but not the U.S., where CTLM is awaiting FDA review as part of the premarket approval process. The application is expected to be complete early this year. Imaging Diagnostic Systems is seeking a PMA for the system to be used as an adjunct to conventional mammography and for clinical examination to aid in the detection of breast abnormalities.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
October 1st 2024Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.